Intramuscular patient-derived xenografts achieve high engraftment rates in gastric cancer: implications for pharmacodynamic testing and genomic biomarker discovery.
Summary
This study developed and evaluated an optimized intramuscular patient-derived xenograft (PDX) platform for gastric cancer. The model achieved a high engraftment rate of 71.7%, significantly exceeding conventional methods. Researchers utilized whole exome sequencing to identify divergent driver mutations between fast- and slow-growing tumors. The findings suggest that PDX-guided chemotherapy selection is associated with improved progression-free survival, and that driver mutation profiles can serve as prognostic biomarkers.
Analysis
🔴 CLINIQUE : This study evaluates an optimized PDX platform for individualized drug testing in gastric cancer. The association between PDX-guided treatment and improved progression-free survival (p = 0.02) suggests significant clinical utility for functional drug sensitivity testing. The identified driver mutations, correlated with tumor growth kinetics and prognosis, could serve as prognostic biomarkers, potentially justifying clinical trials to validate their role in patient stratification and therapeutic selection. Clinical impact could be seen within 3-5 years, integrating these models into personalized medicine workflows. 🟢 BIOMOL : The intramuscular PDX platform represents a major technical advancement, achieving a 71.7% engraftment rate for gastric cancer, significantly higher than the 10-30% reported for subcutaneous approaches. This improved modeling efficiency allows for better preservation of parental tumor molecular features. Whole exome sequencing (WES) was employed to discover distinct driver mutation profiles (KMT2C, APOB, CDK12, MSH2 in fast-growing tumors; TP53, CHD3, TET2 in slow-growing ones), offering new potential targets and prognostic biomarkers. This translational approach could validate clinical tests for targeted therapy selection.